Swedish biotech company AAX Biotech AB announces a collaboration with Daiichi Sankyo, one of the global leaders in antibody-drug conjugates (ADCs), to investigate the potential of its proprietary Opti-mAb® technology for innovative antibody therapeutics.
AAX Biotech pioneers innovative technologies that advance the development of next-generation antibody therapeutics. Its two platforms, Seqitope® and Opti-mAb®, address key challenges in antibody engineering and therapeutic design, supporting the creation of more effective and developable medicines.
Daiichi Sankyo through its Daiichi Sankyo Research Institute in Munich will evaluate the capabilities of Opti-mAb® and explore opportunities for broader collaboration aimed at addressing critical unmet medical needs. AAX Biotech’s unique Opti-mAb® platform stabilizes the inherently unstable single-chain variable fragment (scFv) antibodies.
This collaboration highlights AAX Biotech commitment to exploring cutting-edge science to advance precision medicine and improve patient outcomes worldwide.
